Catalent agrees to commercially supply Palatin Technologies' new bremelanotide pen injector product

Bremelanotide is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women.

Bremelanotide, an on-demand, subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. Phase III clinical trials are on-going, with a commercial launch anticipated in 2018.

“We are pleased that Palatin has chosen to partner with Catalent to commercialize this new and innovative treatment,” commented Jonathan Arnold, Catalent’s Vice President and General Manager for Advanced Delivery Technologies. “Catalent provides flexible manufacturing solutions to meet our customers’ unique program requirements, and our expertise in sterile filling, device and delivery technologies, combined with our packaging capabilities, will facilitate bringing this important product to market faster.”

“We selected Catalent as our partner because of their proven expertise in custom sterile manufacturing solutions, and their track record of successful new product introductions,” added Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin. “Catalent provides the infrastructure, technical expertise and flexibility to support commercialization of this novel product.”

The bremelanotide pen devices will be produced at Catalent's 265,000 sq. ft. Brussels, Belgium site — the company’s flagship sterile fill finish facility, with a syringe-filling capacity of over 100 million units.